Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 10;6(1):vdae155.
doi: 10.1093/noajnl/vdae155. eCollection 2024 Jan-Dec.

Treatment-related survival patterns in diffuse intrinsic pontine glioma using a historical cohort: A report from the European Society for Pediatric Oncology DIPG/DMG Registry

Joshua N Baugh  1 , Sophie Veldhuijzen van Zanten  2   1 , Marta Fiocco  3   4   1 , Niclas Colditz  5 , Marion Hoffmann  5 , Geert O Janssens  6   1 , Chiara Valentini  7   8   5 , Darren Hargrave  9 , Maria Wiese  5 , André O von Bueren  10 , Michael Karremann  11 , Thomas Perwein  12 , Gunther Nussbaumer  12 , Martin Benesch  12 , Dominik Sturm  13   14   15 , Gerrit H Gielen  16 , Mechthild Krause  17   18   7 , Matthias Eyrich  19 , Eelco W Hoving  20   1 , Brigitte Bison  21 , Dannis G van Vuurden  1 , Christof M Kramm  5
Affiliations

Treatment-related survival patterns in diffuse intrinsic pontine glioma using a historical cohort: A report from the European Society for Pediatric Oncology DIPG/DMG Registry

Joshua N Baugh et al. Neurooncol Adv. .

Abstract

Background: Our aim is to investigate the association of treatment with survival in patients with diffuse intrinsic pontine glioma (DIPG) by examining 6 historical treatment paths.

Methods: We retrospectively analyzed data from 409 patients with radiologically centrally reviewed DIPG, sourced from the German Society of Pediatric Oncology and Hematology HIT-HGG trial database and the SIOPE-DIPG/DMG Registry. Survival outcomes were estimated using the Kaplan-Meier method, and univariable and multivariable Cox proportional hazard models were estimated to study treatment effects.

Results: The median overall survival (OS) from diagnosis was 11.2 months (95% confidence interval [CI], 10.5-11.9). Patients who by choice received no frontline treatment had an OS of 3.0 months (95% CI, 2.0-4.0), while those treated with radiation therapy (RT) alone had a median OS of 10.4 months (95% CI, 9.1-11.8). Those receiving RT combined with chemotherapy had the longest median OS of 11.7 months (95% CI, 10.8-12.6). The median post-progression survival (PPS) was 4.1 months (95% CI, 3.5-4.7). Patients who relapsed and did not receive treatment had a PPS of 2.2 months (95% CI, 1.8-2.6), while those treated with chemotherapy alone had a PPS of 4.4 months (95% CI, 3.7-5.0), and those who underwent reirradiation, with or without chemotherapy, had the longest survival after relapse of 6.6 months (95% CI, 5.3-8.0). Treatment differences remained significant in multivariable analysis adjusted for age and symptom duration in both diagnosis and relapse setting.

Conclusions: This study shows increased survival outcomes associated with radiation and chemotherapy treatment or a combination thereof, at diagnosis and relapse, in a historical DIPG cohort.

Keywords: DIPG; diffuse intrinsic pontine glioma; diffuse midline glioma; historical control; registry.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Figure 1.
Figure 1.
Estimated Kaplan–Meier survival time from (A) diagnosis (n = 409) and (B) relapse (n = 342).
See this image and copyright information in PMC

References

    1. Langmoen IA, Lundar T, Storm-Mathisen I, Lie SO, Hovind KH.. Management of pediatric pontine gliomas. Childs Nerv Syst. 1991;7(1):13–15. - PubMed
    1. Bennett J, Erker C, Lafay-Cousin L, et al. Canadian pediatric neuro-oncology standards of practice. Front Oncol. 2020;10(593192):1. - PMC - PubMed
    1. El-Khouly FE, Veldhuijzen van Zanten SEM, Santa-Maria Lopez V, et al. Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand? J Neurooncol. 2019;145(1):177–184. - PMC - PubMed
    1. Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, et al. Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the International and European Society for Pediatric Oncology DIPG Registries. J Clin Oncol. 2018;36(19):1963–1972. - PMC - PubMed
    1. van Walraven C, Davis D, Forster AJ, Wells GA.. Time-dependent bias was common in survival analyses published in leading clinical journals. J Clin Epidemiol. 2004;57(7):672–682. - PubMed

LinkOut - more resources